Over 50 Years of Specialty Injectables
American Regent develops, manufactures and supplies high-quality sterile injectables for healthcare providers and their patients.
Dedicated to Alleviating Drug Shortages
We are committed to collaborating with the FDA to prevent or mitigate drug shortages that impact the health of patients.
Check Product Availability
Updated September 22, 2021 02:17 PM
Melville, NY – September 2, 2021: American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP). Multrys™ is indicated in neonatal and pediatric patients weighing less than 10 kg as a source of zinc, copper, manganese, and selenium for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.
American Regent Introduces HydrALAZINE Hydrochloride Injection, USP; “AP” Rated and Therapeutically Equivalent to Apresoline®1, 2
Melville, NY – July 1, 2020: – American Regent announces the introduction and availability of HydrALAZINE Hydrochloride Injection, USP—“AP” Rated and therapeutically equivalent to Apresoline® 1,2.
Shirley, NY – April 1, 2021: Paul Diolosa assumed the role of President and CEO of American Regent, Inc., a Daiichi Sankyo Group company, effective today.